Annette Langer-Gould to Sweden
This is a "connection" page, showing publications Annette Langer-Gould has written about Sweden.
Connection Strength
0.233
-
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021 12 01; 4(12):e2136697.
Score: 0.052
-
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
Score: 0.048
-
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 05; 87(5):688-699.
Score: 0.046
-
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 02 01; 77(2):184-191.
Score: 0.045
-
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations. Epidemiology. 2019 03; 30(2):230-233.
Score: 0.043